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BACKGROUND: The aim of this study was to elucidate the prognostic impact of putative cancer stem cell markers CD133, CD166,
CD44s, EpCAM, and aldehyde dehydrogenase-1 (ALDH1) in colorectal cancer.
METHODS: A tissue microarray of 1420 primary colorectal cancers and 57 normal mucosa samples was immunostained for CD133,
CD166, CD44s, EpCAM, and ALDH1 in addition to 101 corresponding whole tissue sections. Invasive potential of three colorectal
cancer cell lines was tested.
RESULTS: Differences between normal tissue and cancer were observed for all markers (Po0.001). Loss of membranous CD166 and
CD44s were linked to higher pT (P¼0.002, P¼0.014), pN (P¼0.004, P¼0.002), an infiltrating growth pattern (Po0.001,
P¼0.002), and worse survival (P¼0.015, P¼0.019) in univariate analysis only. Loss of membranous EpCAM expression was also
linked to higher pN (P¼0.023) and infiltrating growth pattern (P¼0.005). The CD44s, CD166, and EpCAM expression were lost
towards the invasive front. The CD44 /CD166  cells from three colorectal cancer cell lines exhibited significantly higher invasive
potential in vitro than their positive counterparts.
CONCLUSIONS: Loss, rather than overexpression, of membranous CD44s, CD166, and EpCAM is linked to tumour progression. This
supports the notion that the membranous evaluation of these proteins assessed by immunohistochemistry may be representative of
their cell adhesion rather than their intra-cellular functions.
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Increasing evidence suggests that, similar to normal tissues,
cancers might also be hierarchically organised. Only a minority
of tumour cells, endowed with stem cell-like features, and thus
termed cancer stem cells (CSCs), might be responsible for tumour
initiation and maintenance (Reya et al, 2001; Pardal et al, 2003;
Dalerba et al, 2007a; Visvader and Lindeman, 2008). Notably,
owing to their high expression of DNA repair mechanisms,
detoxifying enzymes, such as aldehyde dehydrogenase-1 (ALDH1),
and molecular pumps, CSCs might survive radiochemotherapies;
thus, possibly causing local recurrences and metastasis formation
despite treatment (Dean et al, 2005; Dalerba et al, 2007a; Zhou
et al, 2009).
Putative CSC populations have been identified in several types
of solid tumours, on the basis of the expression of specific markers
and on functional stem cell-like properties, including high
clonogenicity, differentiation capacity, spheroid formation, and,
critically, the ability to reproduce the original tumour on
transplantation in immunodeficient mice (Dalerba et al, 2007a;
Visvader and Lindeman, 2008).
Phenotypic characterisation of CSCs derived from colorectal
cancers is still debated. While initial works identified CD133
molecule as a reliable CSC marker in primary human colorectal
cancers (O’Brien et al, 2007; Ricci-Vitiani et al, 2007), a subsequent
study has shown that in both mouse and human colorectal cancers,
CD133 expression is not restricted to rare cell subsets, but it is
detectable in a large majority of tumour cells, irrespective of
their tumourigenicity (Shmelkov et al, 2008). Alternatively, the
co-expression on tumour cells of CD44, CD166, and EpCAM
molecules, has been reported to identify the CSC pool more
precisely than CD133 expression alone (Dalerba et al, 2007b).
Despite the potentially high clinical relevance of CSCs, little is
known about the prognostic value of the expression of putative
CSC markers in colorectal cancers. Contradictory findings have
been reported about the association between the expression of
CD44, in particular of its v6 splicing variant, and tumour
progression (Mulder et al, 1994; Herrlich et al, 1995; Weg-Remers
et al, 1998). In a study based on 111 cases, membranous but not
cytoplasmic expression of CD166 has been found to correlate with
a shortened survival (Weichert et al, 2004). More recently, either a
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expression and clinical outcome has been reported in several
independent studies including limited numbers of cases (Horst
et al, 2008; Kojima et al, 2008; Choi et al, 2009; Li et al, 2009). Still
missing is a comprehensive analysis of the expression of putative
CSC markers in very large groups of patients, amenable to detailed
statistical analysis. Moreover, the prognostic significance of the
co-expression of multiple CSC markers within the same tumour
has not been evaluated so far.
The aim of this study was to elucidate the expression and the
prognostic role of CD133, CD166, CD44s, EpCAM, and ALDH1
expression in colorectal cancer, by using a tissue microarray
including 1420 primary colorectal cancers with full clinicopatho-
logical data and follow-up. Results were further evaluated using
101 corresponding whole tissue sections and three established
colorectal cancer cell lines.
MATERIALS AND METHODS
Patients and clinicopathological data
Archival paraffin-embedded material from 1420 patients with
primary, pre-operatively untreated colorectal cancer were retrieved
from multiple centres including the Institute of Pathology,
University Hospital of Basel, Switzerland; the Institute of Clinical
Pathology, Basel Switzerland; and the Institute of Pathology,
Stadtspital Triemli, Zu ¨rich, Switzerland. All histopathological
information was systematically re-reviewed from the correspond-
ing hematoxylin and eosin slides including pT classification, pN
classification, tumour grade, histological subtype, and the presence
of vascular invasion. Tumour border configuration was diagnosed
according to Jass et al (1987) as ‘pushing /expanding’ when there
was a reasonably well-circumscribed margin at the invasive front
and as ‘infiltrating’ when no recognisable margin of growth and a
streaming dissection between normal structures of the bowel wall
was present. Clinical information was retrieved from patient
records and included age, gender, tumour location, and disease-
specific survival time. For patients diagnosed at the Institute for
Pathology, Stadtspital Triemli, Zu ¨rich, information on local
recurrence (n¼476), distant metastasis (n¼489) and adjuvant
therapy (n¼478) was available. Patient characteristics are
summarised in Table 1. The use of material in this study has been
approved by the local ethics committee.
Tissue microarray and immunohistochemistry
Tumour specimens from all 1420 patients as well as 57 samples of
normal colonic mucosa were included on a previously described
tissue microarray (Zlobec et al, 2009). Tissue cylinders with a
diameter of 0.6mm were punched from morphologically repre-
sentative tissue areas of each ‘donor’ tissue block and brought into
one recipient paraffin block (3 2.5cm) using a homemade
semiautomated tissue arrayer. Immunohistochemistry was
performed for protein markers CD133, CD44s, CD166, EpCAM,
and ALDH1. Detailed procedures have been described elsewhere
(Zlobec et al, 2007a). The following primary antibodies were used:
anti-human CD133 (clone C24B9; 1:100; Cell Signaling, Allschwil,
Swizerland), anti-human CD166 (clone M0G/07; 1:200; Novocastra,
Newcastle, UK), anti-human CD44s (clone DF1485; 1:50; Dako,
Glostrup, Denmark), anti-human EpCAM (clone VU-1D9; 1:200;
Novocastra), and anti-human ALDH1 isoform a1(polyclonal;
1:500; AbCam, Cambridge, UK). Negative controls underwent
the same protocol with the primary antibody omitted.
Evaluation of immunohistochemistry
For CD133, CD166, CD44s, and EpCAM, only membranous
staining was considered, whereas for ALDH1, cytoplasmic
immunoreactivity was evaluated (Figure 1). Tissues were scored
semi-quantitatively by evaluating the proportion of positive
tumour cells over the total number of tumour cells (percentage
of positive tumour cells per tissue microarray punch). Then, using
receiver-operating characteristic (ROC) curve analysis (Zlobec
et al, 2007b), appropriate cutoff scores for each marker were
obtained. Positive staining in percentages of cells above or below
the cutoff scores was classified as ‘overexpression’ or ‘loss’,
respectively. The reliability of the cutoff score was obtained by 200
bootstrapped replications, a method which re-samples the data
with replacement.
Whole tissue sections
A total of 101 whole tissue sections from corresponding colorectal
cancer patients included on the tissue microarray were retrieved
and immunohistochemistry for the markers found to have
prognostic value was performed according to the protocol outlined
above. These cases were part of a previous study used to
investigate the expression of putative stem cell markers within
the regions of most dense tumour budding at the invasive front of
colorectal cancers only (Hostettler et al, 2010). All slides were
scored in the adjacent normal mucosa, if available, tumour centre,
and at the invasive tumour front separately. Differences in
expression pattern were described, namely, whether increased or
decreased expression was observed from the normal adjacent
Table 1 Summary of patient characteristics (n¼1420)
Clinicopathological feature Outcome Frequency N (%)
Age (years; n¼1420) Mean (range) 69.9 (30–96)
Gender (n¼1414) Female 741 (52.4)
Male 673 (47.6)
Histological subtype (n¼1420) Mucinous 119 (8.4)
Other 1301 (91.6)
Tumour location (n¼1400) Right sided 488 (34.9)
Left sided 430 (30.7)
Rectum 482 (34.4)
T classification (n¼1387) pT1 62 (4.5)
pT2 203 (14.6)
pT3 899 (64.8)
pT4 223 (16.1)
N classification (n¼1363) N0 711 (52.2)
N1 358 (26.3)
N2 294 (21.6)
Tumour grade (n¼1385) G1 31 (2.2)
G2 1177 (85.0)
G3 177 (12.8)
Vascular invasion (n¼1385) Absent 1002 (72.4)
Present 383 (27.7)
Tumour border configuration Infiltrating 871 (62.9)
(n¼1384) Pushing 513 (37.1)
Local recurrence (n¼476) Absent 276 (58.0)
Present 200 (42.0)
Distant metastasis (n¼489) Absent 401 (82.0)
Present 88 (18.0)
Post-operative therapy (n¼478) No 377 (78.9)
Yes 101 (21.1)
Survival time (months) (n¼1379) 5-year survival rate 56.4 (54–59)
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front.
Tumour invasion assay
The colorectal cancer cell lines LS180, SW480, and Colo205 were
cultured in RPMI 1640 medium supplemented, with GlutaMAX,
MEM NEAA, 10mM HEPES, 1mM sodium pyruvate, kanamycin
sulphate, and 10% FCS (all the reagents were from Gibco, Paisley,
UK). For invasion assays, cells were stained with APC-conjugated
anti-CD44s and PE-conjugated anti-CD166 antibodies (BD
Pharmingen, San Jose, CA, USA), and CD44þ/CD166þ or
CD44 /CD166  cell subsets were sorted by flow cytometry. Dead
cells were excluded by DAPI staining. Purity of sorted cells was
X97%. Unsorted tumour cells or sorted subsets were tested for
invasiveness in a chemoinvasion assay (Albini and Benelli, 2007).
Briefly, tumour cells re-suspended in serum-free medium were
seeded in transwell plates on uncoated or matrigel-coated
membranes (8mm pore size, BD Biocoat Tumour invasion assay,
BD Biosciences, San Jose, CA, USA). Medium containing 5% FCS
was seeded in the lower chambers and the cells were incubated at
371C for 20h. Inserts were then removed and numbers of cells
migrated into the lower chambers were quantified by CyQUANT
Cell Proliferation Assay Kit (Invitrogen, Paisley, UK). Percentages
of cell invasion were calculated according to the following formula:
(relative fluorescent units (RFU) of cells invaded through matrigel-
coated membranes/mean RFU of cells migrated through uncoated
membranes) 100.
Statistical analysis
The w
2-tests were carried out for categorical end points. The
product-limit method and log-rank or Wilcoxon tests were used to
assess differences in survival time. The 5-year survival rates and
95% confidence intervals (CI) were obtained. For Cox multiple
regression analysis, the assumption of proportional hazards was
verified before each analysis. Patients with missing clinicopatho-
logical data or with non-evaluable immunohistochemistry were
excluded from the analysis. Hazard ratios (HR) and 95% CI were
obtained to assess the prognostic effect of each protein marker on
outcome. All tests were two-sided and P-values were considered
statistically significant with Po0.05.
RESULTS
Tissue microarray analysis
Normal mucosa vs colorectal cancer The mean percentage of cells
expressing CD133 was 0.5% in normal tissue and it significantly
increased in colorectal tumours (24.7%; Po0.001). Similarly, for
CD44s and CD166, expression in normal tissue was detectable in
4.3 and 41.3% of cells on average, respectively, as compared with
33.1 and 64.4% in tumour (Po0.001). Percentages of EpCAM-
expressing cells were slightly decreased in tumour compared with
normal tissue, with a mean of 95.8 and 100% of positive cells,
respectively (Po0.001). Similar results were noted for ALDH1,
with an average expression of 15.1% in normal tissue as compared
with 10.0% in tumour tissue (Po0.001).
CD133
The CD133 expression was evaluated in 1245 cases. The cutoff
score, based on ROC analysis, was fixed at 5%. Among the
analysed cases, 616 cases (49.5%) displayed overexpression,
whereas the remaining 629 cases (50.5%) showed loss. Neither
overexpression nor loss of CD133 was significantly associated with
tumour progression or survival time.
CD133
ABCD
EFGH
IJ
CD133 CD166 CD166
CD44s CD44s EpCAM EpCAM
ALDH1 ALDH1
Figure 1 Colorectal cancer samples with membranous positivity and corresponding negative staining for CD133 (A and B), CD166 (C and D), CD44s
(E and F), EpCAM (G and H) and cytoplasmic positivity and negativity for ALDH1 (I and J).
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A total of 1274 cases were evaluable for CD166 (Table 2). Cutoff
score was fixed at 65%, based on ROC analysis. Overexpression
was detected in 775 cases (60.8%), whereas in the remaining 499
cases (39.2%), loss of expression was observed. Loss of membra-
nous CD166 was linked to more advanced T classification
(P¼0.002), lymph node metastasis (P¼0.004), an infiltrating
tumour border configuration (Po0.001), and worse overall
survival compared with patients with CD166 overexpression
(P¼0.015; Figure 2A). The 5-year survival rates were 52.9%
(95% CI: 48–57%) and 59.0% (95% CI: 55–63%), respectively. In
multivariable analysis including age, T classification, N classifica-
tion, vascular invasion, tumour border configuration, and
metastasis, loss of membranous CD166 did not show an
independent adverse effect on survival. This was found again
when analysed only with tumour border configuration, suggesting
that the prognostic effect of loss of membranous CD166 in the
tumour centre may be secondary to its association with these
unfavourable prognostic features, in particular with the infiltrating
tumour growth pattern.
CD44s
CD44s expression could be evaluated on 1261 tumours and the
cutoff score was fixed at 5% (Table 2). Of the analysed tumours,
607 (48.1%) showed loss and 654 (51.9%) overexpression. Loss of
membranous CD44s was linked to more advanced T classification
(P¼0.014), lymph node involvement (P¼0.002), the presence of
vascular invasion (P¼0.048), left-sidedness (P¼0.008), and an
infiltrating tumour border (P¼0.002). Furthermore, in 467 cases,
for which information on local recurrence was available, a trend
between loss of CD44s and local recurrence (P¼0.052) was also
observed. The 5-year survival rate for patients with loss of
membranous CD44s was 53.4% (95% CI: 49–58%), considerably
poorer as compared with those with CD44s overexpression, which
was 59.3% (95% CI: 55–63%; P¼0.019) (Figure 2B). However, the
prognostic effect of CD44s was not independent of age,
T classification, N classification, vascular invasion, the tumour
border configuration, or metastasis. As seen for CD166, the
absence of prognostic effect was again found when adjusting solely
for the tumour border configuration. These results seem to
indicate that the unfavourable prognostic impact of loss of
membranous CD44s within the main tumour body may be
secondary to its association with T classification, lymph node
metastasis, the presence of vascular invasion, and the infiltrating
growth pattern.
EpCAM
Membranous EpCAM expression was evaluable in 1278 cases of
which 1145 (89.6%) showed a diffuse staining in 100% of tumour
cells (Table 2). A total of 133 tumours (10.4%) showed loss of
membranous EpCAM (o100% staining, as defined according to
Table 2 Association of membranous CD166, CD44s, and EpCAM with clinicopathological features in colorectal cancer patients.
CD166, N (%) CD44s, N (%) EpCAM, N (%)
Clinicopathological feature Loss Overexpression P-value Loss Overexpression P-value Loss Overexpression P-value
T classification
pT1–2 72 (14.7) 165 (21.7) 0.002 96 (16.0) 137 (21.5) 0.014 23 (18.1) 214 (19.0) 0.814
pT3–4 417 (85.3) 594 (78.3) 503 (84.0) 500 (78.5) 104 (81.9) 914 (81.0)
N classification
pN0 228 (47.4) 417 (55.9) 0.004 275 (47.2) 353 (56.0) 0.002 55 (43.0) 594 (53.6) 0.023
pN1–2 253 (52.6) 329 (44.1) 308 (52.8) 277 (44.0) 73 (57.0) 515 (46.4)
Tumour grade
G1–2 438 (89.9) 658 (86.8) 0.097 611 (88.7) 474 (87.0) 0.361 103 (82.4) 990 (87.8) 0.088
G3 49 (10.1) 100 (13.2) 78 (11.3) 71 (11.0) 22 (17.6) 138 (12.2)
Vascular invasion
Absent 340 (69.8) 564 (74.4) 0.076 418 (69.6) 473 (74.6) 0.048 82 (65.1) 824 (73.1) 0.056
Present 147 (30.2) 194 (25.6) 183 (30.4) 161 (25.4) 44 (34.9) 303 (26.9)
Tumour border configuration
Pushing 140 (28.8) 323 (42.6) o0.001 197 (32.8) 261 (41.3) 0.002 32 (25.4) 429 (38.1) 0.005
Infiltrating 346 (71.2) 435 (57.4) 404 (67.2) 371 (58.7) 94 (74.6) 698 (61.9)
Tumour location
Left sided 328 (66.1) 492 (64.4) 0.529 476 (68.7) 341 (61.4) 0.008 89 (67.4) 737 (65.1) 0.596
Right sided 168 (33.9) 272 (35.6) 217 (31.3) 214 (38.6) 43 (32.6) 395 (64.9)
Local recurrence
Absent 43 (50.6) 201 (60.2) 0.109 133 (54.7) 121 (64.0) 0.052 18 (54.6) 239 (57.7) 0.722
Present 42 (49.4) 133 (39.8) 110 (45.3) 68 (36.0) 15 (45.5) 175 (42.3)
Metastasis
Absent 70 (79.6) 275 (81.4) 0.699 202 (82.5) 159 (82.0) 0.894 23 (69.7) 345 (82.0) 0.084
Present 18 (20.5) 63 (18.6) 43 (17.6) 35 (18.0) 10 (30.3) 76 (18.1)
Survival rate (95% CI)
5 year 52.9 (48-57) 59.0 (55-63) 0.015 53.4 (49-58) 59.3 (55-63) 0.019 54.6 (45-63) 56.6 (53-60) 0.521
Abbreviations: CI¼confidence interval; ROC¼receiver-operating characteristic. Cutoff scores for overexpression derived from ROC curve analysis were 65% for CD166, 5%
for CD44s, and 100% for EpCAM.
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of lymph node metastasis (P¼0.023) and an infiltrating tumour
margin (P¼0.005), as well as with a trend towards higher tumour
grade (P¼0.088) and the presence of vascular invasion
(P¼0.056). Furthermore, in 489 cases, a decreased EpCAM
expression showed a trend towards the presence of distant
metastasis (P¼0.084). No association of EpCAM expression with
survival time was noted either in univariate analysis or after
adjusting for the effect of the tumour border configuration.
ALDH1
Of the 1287 tumours evaluable for cytoplasmic ALDH1 expression,
987 (76.7%) had 0% immunoreactive tumour cells. Overexpression
of ALDH1 expression, defined on the basis of ROC analysis as
425% of positive cells, which was observed in the remaining 300
cases (23.3%), was related to higher tumour grade (P¼0.025) but
not to differences in survival time.
Multi-marker combination CD166/CD44s
Cancer stem cells derived from colorectal cancer have been
reported to co-express several surface markers, in particular
CD166, CD44s, and EpCAM molecules (Dalerba et al, 2007b). It
was therefore interesting for us to evaluate clinical relevance of
simultaneous loss or overexpression of these markers in colorectal
cancer tissues. However, as EpCAM expression was very high in all
cases (mean expression 95.8%) and it did not correlate with
survival time, we mainly focused on co-expression of CD166 and
CD44s molecules. Concomitant loss of CD166 and CD44s
molecules was observed in 276 tumours, whereas the remaining
884 cases displayed various combinations of these two markers
including 275 CD166þ/CD44s  cases, 180 CD166 /CD44sþ
cases, and 429 double-positive cases. Importantly, the 5-year
survival rate for cases displaying loss of both CD166 and CD44s
expression was 48.3% (95% CI: 42–54%), whereas that for the
remaining multi-marker phenotypes was 58.6% (95% CI: 55–62%;
Po0.001) (Figure 2C). Despite this adverse effect and similarity to
each marker alone, the prognostic value of this combination of
CD166 and CD44s did not contribute independent prognostic
information in multivariable analysis, indicating no added benefit
in risk stratification for patients with colorectal cancer in this
series when evaluating double negativity compared with single
negativity and effect on outcome.
Whole tissue sections
The above findings suggested a positive association between loss of
CD166 and CD44s molecules and more unfavourable prognosis. In
view of the fact that surface molecules might be heterogeneously
expressed within colorectal cancer tissues (Haier et al, 2000),
CD166 and CD44s staining was further evaluated on whole tissue
sections from 101 patients previously included on this tissue
microarray (Hostettler et al, 2010). We analysed first protein
expression in the tumour centre as compared with normal adjacent
mucosa. Indeed, increased expression of CD166 and CD44s in the
tumour centre compared with normal mucosa occurred in 65 of 89
(73%; Po0.001) and 56 of 89 (62.9%; P¼0.008) cases, respectively,
thus confirming our tissue microarray findings. Next, we
compared protein expression in the tumour centre with that at
the tumour invasive front. Our results indeed showed a hetero-
geneous expression pattern for both CD166 and CD44s. In
particular, decreased expression from the tumour centre to the
tumour border was observed in 51 of 100 cases for CD166 and in
47 of 99 cases for CD44s. Importantly, 80.4% (Po0.001) of cases
showing reduced expression of CD166 and 78% (Po0.001) of
those showing reduced expression of CD44s had an infiltrating
border configuration, thus, confirming a positive association
between loss of CD166 or CD44s and tumour spreading. Third,
we evaluated whether this expression pattern resulted in a poorer
effect on survival. Patients with tumours showing decreased levels
of CD166 or CD44s expression towards the invasive tumour front
when compared with the tumour centre had a significantly more
adverse outcome compared with those with no loss of either
marker (P¼0.006) (Figure 3). Notably, this result was maintained
in multivariable analysis with the tumour border configuration. In
particular, HR (95% CI) for the combined analysis of CD166/
CD44s and tumour border configuration were 4.32 (1.3–14.3;
Time (months)
A
B
C
P<0.001
P=0.019
P=0.015
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
Loss of CD166
Loss of CD44
Loss of both CD166 and CD44
No loss of both 
CD166 or CD44
No loss of CD44
No loss of CD166
0 1 02 03 04 05 06 07 08 0
0 10 20 30 40 50 60 70 80
Time (months)
0 10 20 30 40 50 60 70 80
Time (months)
0.0
0.25
0.5
0.75
1.0
0.0
0.25
0.5
0.75
1.0
0.0
0.25
0.5
0.75
1.0
Figure 2 Kaplan–Meier survival curves illustrating survival time differ-
ences in patients with (A) loss vs overexpression of membranous CD166,
(B) loss vs overexpression of CD44s, and (C) loss of both CD166 and
CD44s vs all other combinations (loss of either CD166 or CD44s or none)
on tissue microarray.
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that the poorer outcome in patients with an expression pattern
showing a loss of CD166 and CD44s expression towards the
invasive front, although highly linked to tumour growth pattern,
may be independent of this histological parameter. Thus, despite
the possible heterogeneity between expression levels in the tumour
centre and tumour front, a diminished expression of CD166 and
CD44s seemed to be consistently associated with tumour progres-
sion and unfavourable clinical outcome.
Invasiveness of tumour cells differing in CD44s and CD166
expression
As CD44s and CD166 are adhesion molecules, we hypothesised
that their loss might directly favour the invasiveness of tumour
cells, possibly as a consequence of reduced adhesion (Figure 4). To
address this issue in a controlled ‘in vitro’ model, we investigated
the invasive potential of CD44þ/CD166þ or CD44 /CD166 
cells derived from the human colorectal cancer cell lines, LS180,
SW480, and Colo205. All three cell lines displayed a heterogeneous
surface expression of CD44 and CD166 (Figure 4, left panels).
However, when CD44þ/CD166þ and CD44 /CD166  cell
subsets were sorted and evaluated for their invasive capacity, in
all cases, the double-negative fractions exhibited significantly
higher invasive potential than their positive counterparts (Figure 4,
right panels). These results suggest that absence of CD44 and
CD166 molecules is directly associated with higher invasive
capacity of tumour cells.
DISCUSSION
In this study, we have evaluated the relationship between
expression of five putative CSC markers and the most clinically
relevant features of colorectal cancer. Our findings suggest that,
despite the increased expression of some of these markers,
including CD133, CD166, and CD44s, from normal to early
colorectal cancer, it is the overall decreased membranous
expression, particularly of EpCAM, CD166, and CD44s, which is
linked to a more aggressive tumour phenotype.
The CD44s has long been thought of as a marker of tumour
invasiveness and metastasis and recently has also been described
as a putative colorectal CSC marker (Visvader and Lindeman,
2008). Many early works investigating the CD44s gene and its
splice variants report a poorer impact on survival time in patients
with increased expression levels of the gene or protein (Mulder
et al, 1994; Wielenga et al, 1998). However, more recent results are
far from unanimous, suggesting either no role for CD44s
(or variant isoforms) or a worse clinical outcome with loss of
protein expression (Coppola et al, 1998; Morrin and Delaney, 2002;
Ngan et al, 2007; Choi et al, 2009; Huh et al, 2009). Others describe
an increased expression of CD44s from normal to adenoma to
carcinoma, a finding that is in line with the results of this study
including normal and tumour tissue (Coppola et al, 1998;
Weg-Remers et al, 1998). Relatively fewer studies have evaluated
the prognostic impact of CD166 in colorectal cancer. Weichert et al
(2004) described increased expression of CD166 from normal to
tumour tissue, and, in a group of 111 colorectal cancer cases,
observed correlation between membranous, but not cytoplasmic,
CD166 expression and shortened survival. Patel et al (2009) also
found a significant increase in CD166 expression in adenomatous
glands and an age-dependent increase in CD44s and CD166
expression, correlating further with the number of polyps. Their
findings suggest a role for CD44s and CD166 in tumour
development from the pre-cancerous state.
Although, in this study, we confirm the increased expression of
both CD44s and CD166 from normal adjacent colorectal tissue to
cancer, our results support the association of loss (rather than
increase) of membranous CD44s and CD166 with aggressive
tumour-related features such as more advanced pT stage, pN stage,
vascular invasion, and an infiltrating tumour growth pattern. In
addition, we document a poorer survival time with loss of
membranous expression of both these protein markers in
univariate but not multivariable survival time analysis, indicating
that the poor prognostic impact of CD44s and CD166 may be
secondary to their association with other established prognostic
criteria. A similar result has been reported in other tumour types,
including ovarian and prostate cancer (Kristiansen et al, 2003;
Mezzanzanica et al, 2008). Expression of EpCAM has previously
been linked to poorer survival time in several tumour types
including breast cancer (Gastl et al, 2000), gallbladder tumours
(Prince et al, 2008), and those of the Papilla Vateri (Scheunemann
et al, 2007; Prince et al, 2008). On investigating rectal cancers,
Gosens et al (2007) found strong membranous EpCAM staining in
the tumour centre and a progressive loss at the tumour front
associated with high tumour grade, tumour budding, and a poor
local and distant recurrence-free survival. In the present study, the
decreased EpCAM expression was also found to be significantly
linked to features of tumour invasion, including presence of lymph
node metastasis and infiltrating tumour margin, and it showed a
trend with higher tumour grade, presence of vascular invasion, and
presence of distant metastasis. Altogether, these studies suggest
that diminished EpCAM expression is related to tumour invasive-
ness and progression.
We hypothesise that our findings concerning decreased (rather
than increased) expression of membranous CD166, CD44s, and
EpCAM and their association with features of tumour progression
are in large part a result of their cell adhesion function. Loss of cell
adhesion is known to be a fundamental mechanism underlying the
initiation of the metastatic process (Woodhouse et al, 1997). In
fact, decreased expression of other cell adhesion molecules such as
E-cadherin and CD44v6, are lost at the invasive front of colorectal
cancer (Ngan et al, 2007; Zlobec et al, 2007a). Moreover, loss of
E-cadherin expression is highlighted as a key event in epithelial–
mesenchymal transition (EMT) (Brabletz et al, 2005a). In color-
ectal cancer, EMT-derived tumour cells are histologically repre-
sented by the presence of ‘tumour budding’ at the invasive front
and are almost always present in tumours with an infiltrating
tumour growth pattern. Tumour budding cells are defined as
single cells or small clusters of de-differentiated tumour cells
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Figure 3 Kaplan–Meier survival curves illustrating survival time differ-
ences in patients with loss of both CD166 and CD44s vs all other
combinations (loss of either CD166 or CD44s or none) on whole tissue
sections.
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s(Prall, 2007) and are thought to represent migratory stem cells
(Brabletz et al, 2005b). High numbers of tumour budding cells are
recognised as independent and adverse prognostic features as their
presence is predictive of vascular and lymphatic invasion (Prall,
2007). In our previous study directly focusing on the expression of
putative stem cell markers in EMT-derived tumour cells, we
describe a low frequency of CD44s, CD166, and EpCAM staining
within tumour buds, thus emphasising the loss of cell adhesion
molecules typical of these cells (Hostettler et al, 2010). Here, we
find that even within representative regions of the main tumour
body obtained using TMA analysis, loss of CD44s, CD166, and
EpCAM is associated with more aggressive tumour-related features
and not surprisingly with an infiltrating growth pattern, an
observation which is directly in line with the low frequency found
within tumour buds. Moreover, using whole tissue sections, we
report the same dynamic and findings, namely, the correlation
between loss of expression of CD44s and CD166 towards the
invasive front and poorer clinical outcome. Our results support
the notion that the evaluation of membranous CD44s, CD166, and
EpCAM expression assessed by immunohistochemistry may be
representative of their cell adhesion function.
We could not confirm the prognostic value of CD133 or ALDH1
in this study (Ginestier and Wicha, 2007; Horst et al, 2008, 2009;
Kojima et al, 2008; Choi et al, 2009; Huang et al, 2009). Several
reasons for these discrepancies can be hypothesised including
differences in sample size (power for detecting prognostic
differences), methodology (tissue microarray vs whole tissue
sections), and certainly the choice of cutoff scores for the
definition of positive staining or staining intensity. Moreover,
the intra-cellular localisation of the evaluated staining (membra-
nous/cytoplasmic) must also be discussed. For example, although
EpCAM, similar to CD44, is known for its cell adhesion function
(membranous localisation), it seems to have versatile roles in
signalling, cell migration, proliferation, and differentiation,
depending on the microenvironment (cytoplasmic localisation)
(Trzpis et al, 2007).
A few factors might be envisaged as potential limitations of our
study. First, information on local recurrence, distant metastasis,
and post-operative therapy was only available for patients treated
at one diagnostic centre. However, the lack of independent
prognostic effects for our two main CSC markers of interest,
namely, CD166 and CD44s, suggest that the absence of complete
treatment information may only minimally influence our findings.
The results of this study also highlight a heterogeneous expression
of CD166 and CD44s throughout the tumour. These findings
suggest that using single-punch tissue microarray analysis to
investigate these and likely other cell adhesion molecules may be
suboptimal. Nonetheless, using two additional and different
approaches, namely, analysis of whole tissues sections and
in vitro analysis using three cell lines, we could show similar
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Figure 4 The CD44 /CD166  tumour cells display higher invasive potential than CD44þ/CD166þ cells. The CD44 /CD166  and CD44þ/
CD166þ cell subsets were sorted by flow cytometry, according to the gates depicted, from LS180, SW480, and Colo205 cell lines. Sorted subsets were
tested in invasion assays. Percentages of cell invasion (mean values±s.d.) are shown. Data are representative of six independent experiments.
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sfindings. Although established cell lines might not fully reproduce
the behaviour of primary tumours, our in vitro findings strongly
suggest that CD44s and CD166 are of functional importance in
limiting tumour cell spreading in surrounding tissues, thus
underlining the hypothesis that loss of expression of these
markers, rather than their overexpression, is associated with a
more aggressive tumour phenotype.
To our knowledge, this is the first systematic assessment of the
prognostic value of CD133, CD166, CD44, EpCAM, and ALDH1 in
colorectal tumours evaluated on a large number of cases. Our
findings indicate that expression of CSC markers is not per se
predictive of poor clinical outcome. Loss of expression of CD166,
CD44s, and EpCAM is rather linked to an aggressive tumour
phenotype, particularly, to the presence of an infiltrating tumour
margin that may implicate these proteins and their loss of
membranous expression in events occurring at the invasive
tumour front.
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